Brukinsa
September 23, 2026 at 2:53 AM
Brukinsa
📄 #ONC 10-Q — what changed
MD&A now says: "Key highlights for the second quarter of 2026 are as follows: • Second quarter 2026 total global revenues increased 30% to $1.7 billion versus second quarter 2025 • Global BRUKINSA ® (zanubrutinib) revenues increased 31% to $1.2 billion ve
MD&A now says: "Key highlights for the second quarter of 2026 are as follows: • Second quarter 2026 total global revenues increased 30% to $1.7 billion versus second quarter 2025 • Global BRUKINSA ® (zanubrutinib) revenues increased 31% to $1.2 billion ve
FormDelta — Insider Trading Alerts
What BeOne Medicines Ltd. changed in their own words, quarter over quarter.
www.formdelta.com
September 10, 2026 at 8:58 PM
📢 Beigene is #hiring a Senior Manager, Marketing – Brukinsa!
🌎 Worldwide
👵 Senior
🔗 http://jbs.ink/rh6xERN4ZzYB
#jobalert #jobsearch #aviationjobs #remotejob #remotework #wfh #aws #marketing
🌎 Worldwide
👵 Senior
🔗 http://jbs.ink/rh6xERN4ZzYB
#jobalert #jobsearch #aviationjobs #remotejob #remotework #wfh #aws #marketing
September 6, 2026 at 8:50 PM
📢 Beigene is #hiring a Senior Manager, Marketing – Brukinsa!
🌎 Worldwide
👵 Senior
🔗 http://jbs.ink/rh6xERN4ZzYB
#jobalert #jobsearch #aviationjobs #remotejob #remotework #wfh #aws #marketing
🌎 Worldwide
👵 Senior
🔗 http://jbs.ink/rh6xERN4ZzYB
#jobalert #jobsearch #aviationjobs #remotejob #remotework #wfh #aws #marketing
BeOne Medicines Pivots R&D, Slashes BRUKINSA Funding for Next-Gen Assets https://signalbloom.ai/news/ONC/beone-medicines-pivots-rd-slashes-brukinsa-funding-for-next-gen-assets $ONC #Earnings via @signalbloom.ai
August 26, 2026 at 10:18 AM
BeOne Medicines Pivots R&D, Slashes BRUKINSA Funding for Next-Gen Assets https://signalbloom.ai/news/ONC/beone-medicines-pivots-rd-slashes-brukinsa-funding-for-next-gen-assets $ONC #Earnings via @signalbloom.ai
Partnership expands access to CLL treatment in low-, middle-income countries
sohoinsider.com/news/partner...
sohoinsider.com/news/partner...
Partnership expands access to CLL treatment in low-, middle-income countries
An initiative between BeOne Care Foundation and The Max Foundation has been renewed through 2028 to expand global access to zanubrutinib (Brukinsa) for patients with chronic lymphocytic leukemia in…
sohoinsider.com
August 20, 2026 at 6:32 PM
Partnership expands access to CLL treatment in low-, middle-income countries
sohoinsider.com/news/partner...
sohoinsider.com/news/partner...
📰 #Finance
"Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028 SAN CARLOS, Calif. & SEATTLE — BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global…"
"Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028 SAN CARLOS, Calif. & SEATTLE — BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global…"
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
financialpost.com
August 18, 2026 at 11:30 AM
I was diagnosed with CLL (Chronic Lymphocytic Leukemia) in 2009. I've had chemo 5 times. Each time it knocked back the bad lymphocytes and they gradually came back. Now I'm on Brukinsa, which has my blood numbers in the normal range. Quality of life has mostly been excellent, Thank God for insurance
August 9, 2026 at 2:47 AM
I was diagnosed with CLL (Chronic Lymphocytic Leukemia) in 2009. I've had chemo 5 times. Each time it knocked back the bad lymphocytes and they gradually came back. Now I'm on Brukinsa, which has my blood numbers in the normal range. Quality of life has mostly been excellent, Thank God for insurance
📰 #Finance
"Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year Diluted GAAP Earnings per American Depository Share (ADS) of…"
"Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year Diluted GAAP Earnings per American Depository Share (ADS) of…"
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
financialpost.com
August 5, 2026 at 11:26 AM
📰 #Finance
"Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year Diluted GAAP Earnings per American Depository Share (ADS) of…"
"Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year Diluted GAAP Earnings per American Depository Share (ADS) of…"
📢 Beigene is #hiring a Director, Hcp Marketing Promotions, Brukinsa!
🌎 United States
🔗 http://jbs.ink/ynCr7TIYXlPk
#jobalert #jobsearch #ecommercejobs #aws #marketing
🌎 United States
🔗 http://jbs.ink/ynCr7TIYXlPk
#jobalert #jobsearch #ecommercejobs #aws #marketing
July 13, 2026 at 5:17 PM
📢 Beigene is #hiring a Director, Hcp Marketing Promotions, Brukinsa!
🌎 United States
🔗 http://jbs.ink/ynCr7TIYXlPk
#jobalert #jobsearch #ecommercejobs #aws #marketing
🌎 United States
🔗 http://jbs.ink/ynCr7TIYXlPk
#jobalert #jobsearch #ecommercejobs #aws #marketing
Jefferies upgrades #$ONC from Hold to Buy and raises price target to $380, implying 27% upside. Strong Brukinsa outlook and solid tumor pipeline drive bullish view. notreload.xyz/xy/analyst-u...
Jefferies Upgrades BeOne Medicines (ONC) to Buy, PT $380
Jefferies upgraded BeOne Medicines, citing strong Brukinsa growth, promising cancer drugs, and potential 27% stock upside.
notreload.xyz
July 13, 2026 at 9:41 AM
Jefferies upgrades #$ONC from Hold to Buy and raises price target to $380, implying 27% upside. Strong Brukinsa outlook and solid tumor pipeline drive bullish view. notreload.xyz/xy/analyst-u...
📢 Beigene is #hiring a Director, Hcp Marketing Promotions, Brukinsa!
🌎 Worldwide
🔗 http://jbs.ink/q1vesWNjbhQt
#jobalert #jobsearch #aviationjobs #remotejob #remotework #wfh #aws #marketing
🌎 Worldwide
🔗 http://jbs.ink/q1vesWNjbhQt
#jobalert #jobsearch #aviationjobs #remotejob #remotework #wfh #aws #marketing
July 9, 2026 at 5:01 PM
📢 Beigene is #hiring a Director, Hcp Marketing Promotions, Brukinsa!
🌎 Worldwide
🔗 http://jbs.ink/q1vesWNjbhQt
#jobalert #jobsearch #aviationjobs #remotejob #remotework #wfh #aws #marketing
🌎 Worldwide
🔗 http://jbs.ink/q1vesWNjbhQt
#jobalert #jobsearch #aviationjobs #remotejob #remotework #wfh #aws #marketing
It's great that Mark has provided discounts on so many drugs, but we still need insurance. My meds are not on his list, and cost $14,000 a month (Brukinsa, 320 mg/day). Thankfully it's mostly paid for between Medicare and Highmark insurance.
July 6, 2026 at 11:35 PM
It's great that Mark has provided discounts on so many drugs, but we still need insurance. My meds are not on his list, and cost $14,000 a month (Brukinsa, 320 mg/day). Thankfully it's mostly paid for between Medicare and Highmark insurance.
Zanibrutinib + rituximab reduce el riesgo de progresión de la enfermedad o muerte y mejora la supervivencia libre de progresión en pacientes con linfoma de las células del manto que no pueden ser sometidos a trasplante de células madre firstwordpharma.com/story/7663665
Chemotherapy-free Brukinsa regimen clears Phase III test in frontline MCL | FirstWord PHARMA
BeOne said its BTK inhibitor reduced the risk of progression or death by 43% in patients with previously untreated mantle cell lymphoma.
firstwordpharma.com
July 6, 2026 at 4:59 AM
Zanibrutinib + rituximab reduce el riesgo de progresión de la enfermedad o muerte y mejora la supervivencia libre de progresión en pacientes con linfoma de las células del manto que no pueden ser sometidos a trasplante de células madre firstwordpharma.com/story/7663665
Today's incremental harvest produced a single new article — BeOne's Brukinsa hitting its primary endpoint in a Phase 3 mantle-cell-lymphoma confirmatory trial — while 19 of 20 candidates were already represented in the news…
https://openbionews.com/analysis/daily-bio-news-summary-2026-07-01/
https://openbionews.com/analysis/daily-bio-news-summary-2026-07-01/
August 6, 2026 at 9:53 PM
Today's incremental harvest produced a single new article — BeOne's Brukinsa hitting its primary endpoint in a Phase 3 mantle-cell-lymphoma confirmatory trial — while 19 of 20 candidates were already represented in the news…
https://openbionews.com/analysis/daily-bio-news-summary-2026-07-01/
https://openbionews.com/analysis/daily-bio-news-summary-2026-07-01/
Patients with newly diagnosed #mantlecell #lymphoma (MCL) could avoid chemotherapy with a #regimen based on #BeOneMedicines' #Brukinsa and #rituximab.
pharmaphorum.com/news/brukins...
pharmaphorum.com/news/brukins...
Brukinsa data raise chemo-free hope for mantle cell lymphoma
Patients with newly diagnosed mantle cell lymphoma could avoid chemotherapy with a regimen based on BeOne's Brukinsa, according to the MANGROVE trial.
pharmaphorum.com
June 30, 2026 at 12:52 PM
Patients with newly diagnosed #mantlecell #lymphoma (MCL) could avoid chemotherapy with a #regimen based on #BeOneMedicines' #Brukinsa and #rituximab.
pharmaphorum.com/news/brukins...
pharmaphorum.com/news/brukins...
#ONC BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
https://www.stocktitan.net/news/ONC/be-one-medicines-announces-positive-phase-3-results-for-brukinsa-in-9kv6g1j06qyy.html
https://www.stocktitan.net/news/ONC/be-one-medicines-announces-positive-phase-3-results-for-brukinsa-in-9kv6g1j06qyy.html
BeOne's BRUKINSA cuts progression risk 43% in frontline lymphoma
MANGROVE met its main endpoint in untreated mantle cell lymphoma. BeOne plans global regulatory submissions in 2H 2026 after full results are shared.
www.stocktitan.net
June 30, 2026 at 10:00 AM
#ONC BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
https://www.stocktitan.net/news/ONC/be-one-medicines-announces-positive-phase-3-results-for-brukinsa-in-9kv6g1j06qyy.html
https://www.stocktitan.net/news/ONC/be-one-medicines-announces-positive-phase-3-results-for-brukinsa-in-9kv6g1j06qyy.html
📰 #Finance
"Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment BRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL…"
"Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment BRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL…"
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
financialpost.com
June 12, 2026 at 11:37 AM
📰 #Finance
"Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment BRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL…"
"Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment BRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL…"
#ONC BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
https://www.stocktitan.net/news/ONC/be-one-medicines-foundational-hematology-franchise-leads-next-era-of-gm52pptcvg40.html
https://www.stocktitan.net/news/ONC/be-one-medicines-foundational-hematology-franchise-leads-next-era-of-gm52pptcvg40.html
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
BeOne Medicines (Nasdaq: ONC) reported new EHA 2026 data from its hematology franchise, including BTK degrader tacabrutideg and the all-oral BRUKINSA plus BEQALZI (ZS) combination.Tacabrutideg showed high response rates and manageable safety in heavily pretreated and BTK inhibitor–naïve B‑cell cancers, while ZS achieved high complete response and uMRD rates across treatment‑naïve and relapsed/refractory CLL and MCL.
www.stocktitan.net
June 12, 2026 at 10:00 AM
#ONC BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
https://www.stocktitan.net/news/ONC/be-one-medicines-foundational-hematology-franchise-leads-next-era-of-gm52pptcvg40.html
https://www.stocktitan.net/news/ONC/be-one-medicines-foundational-hematology-franchise-leads-next-era-of-gm52pptcvg40.html
#ONC BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
https://www.stocktitan.net/news/ONC/be-one-showcases-landmark-phase-3-data-in-cll-patients-aged-80-at-lkee19reqac1.html
https://www.stocktitan.net/news/ONC/be-one-showcases-landmark-phase-3-data-in-cll-patients-aged-80-at-lkee19reqac1.html
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
BeOne Medicines (Nasdaq: ONC) reported long-term Phase 3 and real‑world data for BRUKINSA in CLL/SLL, including patients aged 80+.In SEQUOIA patients ≥80, ORR was 100%, 72‑month PFS 63.8% and OS 75.9%, with safety consistent with prior data. Broader 78‑month SEQUOIA results showed PFS 71.8% for BRUKINSA vs 31.0% for bendamustine‑rituximab. Real‑world analyses across more than 250,000 patients linked BRUKINSA to longer time to next treatment, improved survival versus other BTK inhibitors, and lower one‑year atrial fibrillation rates.
www.stocktitan.net
June 11, 2026 at 11:24 AM
#ONC BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
https://www.stocktitan.net/news/ONC/be-one-showcases-landmark-phase-3-data-in-cll-patients-aged-80-at-lkee19reqac1.html
https://www.stocktitan.net/news/ONC/be-one-showcases-landmark-phase-3-data-in-cll-patients-aged-80-at-lkee19reqac1.html
Hi G.R., we don't have access to Brukinsa unfortunately. We hope to add more new drugs soon, but until then you may want to look at the manufacturer's website for savings.
Follow our newsletter for updates on additions:
bit.ly/mccpnewsletter
Follow our newsletter for updates on additions:
bit.ly/mccpnewsletter
bit.ly
June 5, 2026 at 4:07 PM
Hi G.R., we don't have access to Brukinsa unfortunately. We hope to add more new drugs soon, but until then you may want to look at the manufacturer's website for savings.
Follow our newsletter for updates on additions:
bit.ly/mccpnewsletter
Follow our newsletter for updates on additions:
bit.ly/mccpnewsletter
📰 #Finance
"Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy BRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD…"
"Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy BRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD…"
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
financialpost.com
May 29, 2026 at 11:32 AM
📰 #Finance
"Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy BRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD…"
"Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy BRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD…"
#ONC BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
https://www.stocktitan.net/news/ONC/be-one-medicines-establishes-standard-for-long-term-disease-control-6nxy61uu3jbo.html
https://www.stocktitan.net/news/ONC/be-one-medicines-establishes-standard-for-long-term-disease-control-6nxy61uu3jbo.html
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
BeOne Medicines (Nasdaq: ONC) reported 78‑month SEQUOIA data for BRUKINSA in first‑line CLL/SLL at ASCO 2026, showing 78‑month PFS of 71.8% vs 31.0% with bendamustine‑rituximab and favorable PFS2 and TTNT.Real‑world datasets (>250,000 patients) associated BRUKINSA with longer TTNT, improved overall survival, and lower atrial fibrillation rates than other BTK inhibitors. The BRUKINSA plus sonrotoclax (ZS) combo achieved 100% ORR, 59.5% CR, 98.8% uMRD4 and 92.9% uMRD in TP53‑mutated/del(17p) CLL, with median 4.5‑month time to uMRD4 and no progression at the Phase 2 dose.
www.stocktitan.net
May 29, 2026 at 10:00 AM
#ONC BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
https://www.stocktitan.net/news/ONC/be-one-medicines-establishes-standard-for-long-term-disease-control-6nxy61uu3jbo.html
https://www.stocktitan.net/news/ONC/be-one-medicines-establishes-standard-for-long-term-disease-control-6nxy61uu3jbo.html
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts Long-term and real-world evidence reinforce BRUKINSA as the foundation of CLL treatment Three oral presentations at...
#Business #Wire #News #Releases #PMN #Press #Releases
Origin | Interest | Match
#Business #Wire #News #Releases #PMN #Press #Releases
Origin | Interest | Match
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts
Long-term and real-world evidence reinforce BRUKINSA as the foundation of CLL treatment
financialpost.com
May 21, 2026 at 10:28 AM